Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RXC007 + nintedanib
- Development stage
- Phase 2
- Lead developer
- Redx Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
RXC007 + nintedanib is an experimental combination therapy under investigation for fibrotic lung diseases, specifically idiopathic pulmonary fibrosis (IPF) and interstitial lung disease (ILD). RXC007 is a selective, orally active small molecule inhibitor of Rho-associated coiled-coil containing protein kinase 2 (ROCK2), a critical modulator of cellular growth, inflammatory response, and fibrosis, with potential disease-modifying anti-fibrotic effects. Nintedanib is a small molecule tyrosine kinase inhibitor (TKI) that targets multiple growth factor receptors (FGFR, VEGFR, PDGFR, CSF1R, and FLT3), suppressing fibroblast proliferation and migration and thus slowing fibrosis progression. Both are administered orally and are being evaluated together to assess potential additive or synergistic anti-fibrotic benefit in clinical studies[1][2][7].
- Brand names
- Ofev (for nintedanib)
- Other names
- nintedanib
02
Targets
FGFR (Fibroblast growth factor receptor)PDGFR (PDGFR family)ROCK2 (Rho-associated coiled-coil containing protein kinase 2)SFK (SRC family kinases)TGFBR2 (TGF-β receptor type 2)VEGFR (VEGFR family)CSF1R (Macrophage colony-stimulating factor receptor)FGFR (FGFR family)FLT3 (Fms related receptor tyrosine kinase 3)
Beyond the preview
Go deeper on RXC007 + nintedanib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RXC007 + nintedanib.